{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T16:14:17Z","timestamp":1779898457281,"version":"3.53.1"},"reference-count":70,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,1,29]],"date-time":"2019-01-29T00:00:00Z","timestamp":1548720000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.clinthera.2018.12.013","type":"journal-article","created":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T01:49:35Z","timestamp":1548812975000},"page":"336-349","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["The Case for Real-world Evidence in the Future of Clinical Research on Chronic Myeloid Leukemia"],"prefix":"10.1016","volume":"41","author":[{"given":"Jonathan","family":"Webster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. Douglas","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2018.12.013_bib1","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","article-title":"Real-world evidence\u2014what is it and what can it tell us?","volume":"375","author":"Sherman","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2018.12.013_bib2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/2040620714560305","article-title":"The role of observational studies in optimizing the clinical management of chronic myeloid leukemia","volume":"6","author":"Mauro","year":"2015","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.clinthera.2018.12.013_bib3","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/bjc.2013.725","article-title":"Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence","volume":"110","author":"Booth","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clinthera.2018.12.013_bib4","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood-2010-10-309807","article-title":"Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy","volume":"117","author":"Ibrahim","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2018.12.013_bib5","unstructured":"US Food and Drug Administration. Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices: Guidance for Industry and Food and Drug Administration Staff. Available at: https:\/\/www.fda.gov\/downloads\/medicaldevices\/deviceregulationandguidance\/guidancedocuments\/ucm513027.pdf. Accessed 2 October 2017."},{"issue":"suppl 2","key":"10.1016\/j.clinthera.2018.12.013_bib6","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1513\/AnnalsATS.201308-276RM","article-title":"Complementing the randomized controlled trial evidence base. evolution not revolution","volume":"11","author":"Price","year":"2014","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.clinthera.2018.12.013_bib7","unstructured":"Berger M, Daniel G, Frank K, et\u00a0al; Duke-Margolis Center for Health Policy. A Framework for Regulatory Use of Real-World Evidence. Available at: https:\/\/healthpolicy.duke.edu\/sites\/default\/files\/atoms\/files\/rwe_white_paper_2017.09.06.pdf. Accessed 3 April 2018."},{"key":"10.1016\/j.clinthera.2018.12.013_bib8","first-page":"214","article-title":"Health care resource utilization and costs in patients with chronic myeloid leukemia with better adherence to tyrosine kinase inhibitors and increased molecular monitoring frequency","volume":"23","author":"Latremouille-Viau","year":"2017","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1016\/j.clinthera.2018.12.013_bib9","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1002\/ajh.24887","article-title":"First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY","volume":"92","author":"Goldberg","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clinthera.2018.12.013_bib10","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.leukres.2010.07.001","article-title":"Real-life\" results of front-line treatment with imatinib in older patients (\u2265 65 years) with newly diagnosed\u00a0chronic myelogenous leukemia","volume":"34","author":"Latagliata","year":"2010","journal-title":"Leuk Res"},{"key":"10.1016\/j.clinthera.2018.12.013_bib11","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1185\/03007990903479299","article-title":"Management of chronic myeloid leukaemia in clinical practice in France: results of the French subset of patients from the UNIC study","volume":"26","author":"Michallet","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2018.12.013_bib12","unstructured":"US Food and Drug Administration. Drug and device manufacturer communications with payors, formulary committees, and similar entities\u2014questions and answers: guidance for industry and review staff. https:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm537347.pdf. Accessed 10 August 2017."},{"key":"10.1016\/j.clinthera.2018.12.013_bib13","unstructured":"21st Century Cures act, Publication no. 114\u2013255, 130 Stat 1033."},{"key":"10.1016\/j.clinthera.2018.12.013_bib14","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/leu.2016.246","article-title":"Treatment and outcome of 2904 CML patients from the EUTOS population-based registry","volume":"31","author":"Hoffmann","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clinthera.2018.12.013_bib15","series-title":"Registries for evaluating patient outcomes: a user's guide","year":"2014"},{"key":"10.1016\/j.clinthera.2018.12.013_bib16","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1046\/j.1524-4733.2003.00242.x","article-title":"A\u00a0checklist for retrospective database studies--report of the ISPOR task force on retrospective databases","volume":"6","author":"Motheral","year":"2003","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2018.12.013_bib17","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.clinthera.2014.10.019","article-title":"Real-world analysis of tyrosine kinase inhibitor treatment patterns among patients with chronic myeloid leukemia in the United States","volume":"37","author":"Henk","year":"2015","journal-title":"Clin Therapeut"},{"key":"10.1016\/j.clinthera.2018.12.013_bib18","first-page":"63","article-title":"Treatment patterns and healthcare costs among newly-diagnosed patients with chronic myeloid leukemia receiving dasatinib or nilotinib as first-line therapy in the United States","volume":"20","author":"Latremouille-Viau","year":"2017","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.clinthera.2018.12.013_bib19","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ijmedinf.2007.09.001","article-title":"Definition, structure, content, use and impacts of electronic health records: a review of the research literature","volume":"77","author":"H\u00e4yrinen","year":"2008","journal-title":"Int J Med Inf"},{"key":"10.1016\/j.clinthera.2018.12.013_bib20","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00432-017-2372-z","article-title":"Factors influencing adherence in CML and ways to improvement: results of a patient-driven survey of 2546 patients in 63 countries","volume":"143","author":"Geissler","year":"2017","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.clinthera.2018.12.013_bib21","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1524-4733.2007.00186.x","article-title":"Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report","volume":"10","author":"Garrison","year":"2007","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2018.12.013_bib22","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A\u00a0phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2018.12.013_bib23","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1001\/jama.2018.16773","article-title":"Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial","volume":"320","author":"Banerji","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2018.12.013_bib24","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1001\/jamainternmed.2016.7491","article-title":"Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: a randomized clinical trial","volume":"177","author":"Agar","year":"2017","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.clinthera.2018.12.013_bib25","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.clinthera.2018.12.013_bib26","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clinthera.2018.12.013_bib27","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/ajh.22019","article-title":"Nonadherence to imatinib adversely affects event free survival in chronic phase-chronic myeloid leukemia","volume":"86","author":"Ganesan","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clinthera.2018.12.013_bib28","article-title":"Comparison between aspirin and clopidogrel in secondary stroke prevention based on real-world data","volume":"7","author":"Chi","year":"2018","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"suppl 1","key":"10.1016\/j.clinthera.2018.12.013_bib29","article-title":"Management of chronic myeloid leukemia (CML) during pregnancy among patients (pts) treated with a tyrosine kinase inhibitor (TKI): a single-center experience","volume":"130","author":"Assi","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2018.12.013_bib30","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1185\/03007995.2016.1140030","article-title":"Treatment patterns, overall survival, healthcare resource use and costs in elderly Medicare beneficiaries with chronic myeloid leukemia using second-generation tyrosine kinase inhibitors as second-line therapy","volume":"32","author":"Smith","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2018.12.013_bib31","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1185\/03007995.2013.812034","article-title":"Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib","volume":"29","author":"Goldberg","year":"2013","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"10.1016\/j.clinthera.2018.12.013_bib32","first-page":"303","article-title":"Medication adherence, molecular monitoring, and clinical outcomes in patients with chronic myelogenous leukemia in a large HMO","volume":"57","author":"Haque","year":"2003","journal-title":"J\u00a0Am Pharmaceut Assoc"},{"key":"10.1016\/j.clinthera.2018.12.013_bib33","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/leu.2015.261","article-title":"Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia","volume":"30","author":"Pfirrmann","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.clinthera.2018.12.013_bib34","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/leu.2017.63","article-title":"Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study","volume":"31","author":"Hochhaus","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clinthera.2018.12.013_bib35","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.1891.1891","article-title":"Patient-reported quality of life before and after stopping treatment in the ENESTop trial of treatment-free remission for patients with chronic myeloid leukemia in chronic phase","volume":"128","author":"Mahon","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2018.12.013_bib36","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.leukres.2012.09.013","article-title":"Health-related quality of life in chronic myeloid leukemia","volume":"37","author":"Trask","year":"2013","journal-title":"Leuk Res"},{"key":"10.1016\/j.clinthera.2018.12.013_bib37","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.leukres.2011.10.011","article-title":"Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia","volume":"36","author":"Trask","year":"2012","journal-title":"Leuk Res"},{"key":"10.1016\/j.clinthera.2018.12.013_bib38","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1182\/blood-2013-01-477687","article-title":"Measuring the symptom burden associated with the treatment of chronic myeloid leukemia","volume":"122","author":"Williams","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2018.12.013_bib39","first-page":"128","article-title":"Cardiovascular events among patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs)","author":"Sam","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2018.12.013_bib40","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial","volume":"36","author":"Cortes","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clinthera.2018.12.013_bib41","series-title":"Clinical practice guidelines in oncology. Chronic myeloid leukemia. V1.","author":"National Comprehensive Cancer Network","year":"2019"},{"key":"10.1016\/j.clinthera.2018.12.013_bib42","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/leu.2016.115","article-title":"The concept of treatment-free remission in chronic myeloid leukemia","volume":"30","author":"Saussele","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.clinthera.2018.12.013_bib43","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","article-title":"Long-term follow-up of the French Stop Imatinib (STIM1) study in patients with chronic myeloid leukemia","volume":"35","author":"Etienne","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 4","key":"10.1016\/j.clinthera.2018.12.013_bib44","doi-asserted-by":"crossref","first-page":"iv41","DOI":"10.1093\/annonc\/mdx219","article-title":"Chronic myeloid leukemia: EMSO Clinical Practice Guidelines for diagnosis, treatment, and follow-up","volume":"28","author":"Hochhaus","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2018.12.013_bib45","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/M17-1094","article-title":"Treatment-free remission after second-line nilotinib treatment in patients with chronic myeloid leukemia in chronic phase: results from a single-group, phase 2, open-label study","volume":"168","author":"Mahon","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2018.12.013_bib46","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s00432-018-2604-x","article-title":"Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study","volume":"144","author":"Ross","year":"2018","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.clinthera.2018.12.013_bib47","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","article-title":"Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease","volume":"32","author":"Rousselot","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl","key":"10.1016\/j.clinthera.2018.12.013_bib48","article-title":"Tyrosine kinase inhibitor (TKI) therapy discontinuation in patients with CML in chronic phase: a US clinical practice perspective","volume":"35","author":"Ritchie","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clinthera.2018.12.013_bib49","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1056\/NEJM199912303412706","article-title":"Underrepresentation of patients 65 years of age or older in cancer-treatment trials","volume":"341","author":"Hutchins","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2018.12.013_bib50","series-title":"Gleevec (imatinib mesylate) [package insert]","year":"2017"},{"key":"10.1016\/j.clinthera.2018.12.013_bib51","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJM199910143411606","article-title":"Racial differences in the treatment of early-stage lung cancer","volume":"341","author":"Bach","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2018.12.013_bib52","doi-asserted-by":"crossref","first-page":"6639","DOI":"10.1200\/JCO.2005.12.633","article-title":"Racial disparities in treatment and survival among women with early-stage breast cancer","volume":"23","author":"Hershman","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clinthera.2018.12.013_bib53","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0360-3016(00)00440-5","article-title":"Association between age and the utilization of radiotherapy in Ontario","volume":"47","author":"Tyldesley","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clinthera.2018.12.013_bib54","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1200\/JCO.2012.45.4553","article-title":"Patient income level and cancer clinical trial participation","volume":"31","author":"Unger","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clinthera.2018.12.013_bib55","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.clinthera.2007.07.004","article-title":"Importance of observational studies in clinical practice","volume":"29","author":"Ligthelm","year":"2007","journal-title":"Clin Therapeut"},{"key":"10.1016\/j.clinthera.2018.12.013_bib56","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clinthera.2018.12.013_bib57","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1182\/blood-2013-03-490128","article-title":"Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities","volume":"121","author":"Jain","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2018.12.013_bib58","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","article-title":"Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"30","author":"Marin","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clinthera.2018.12.013_bib59","unstructured":"ClinicalTrials.gov. Studying first line treatment of chronic myeloid leukemia (CML) in a real-world setting (SIMPLICITY). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01244750. Accessed 7 May 2018."},{"key":"10.1016\/j.clinthera.2018.12.013_bib60","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/leu.2015.73","article-title":"The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in twenty European countries","volume":"29","author":"Hoffmann","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.clinthera.2018.12.013_bib61","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","article-title":"Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score","volume":"118","author":"Hasford","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2018.12.013_bib62","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1038\/leu.2013.171","article-title":"The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib","volume":"27","author":"Hoffmann","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clinthera.2018.12.013_bib63","doi-asserted-by":"crossref","first-page":"80083","DOI":"10.18632\/oncotarget.11657","article-title":"Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome","volume":"7","author":"Iurlo","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.clinthera.2018.12.013_bib64","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2016-01-694265","article-title":"Moving treatment-free remission into mainstream clinical practice in CML","volume":"128","author":"Hughes","year":"2016","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.clinthera.2018.12.013_bib65","article-title":"Treatment patterns in patients with chronic myeloid leukemia in chronic phase in US clinical practice, with a focus on tyrosine kinase inhibitor therapy discontinuation","volume":"130","author":"Ritchie","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2018.12.013_bib66","series-title":"Tasigna (nilotinib) [package insert]","year":"2018"},{"key":"10.1016\/j.clinthera.2018.12.013_bib67","doi-asserted-by":"crossref","first-page":"161","DOI":"10.7326\/M15-2306","article-title":"Cardiovascular events associated with use of tyrosine kinase inhibitors in chronic myeloid leukemia: a population-based cohort study","volume":"165","author":"Dahl\u00e9n","year":"2016","journal-title":"Ann Intern Med"},{"issue":"suppl 1","key":"10.1016\/j.clinthera.2018.12.013_bib68","article-title":"Atherosclerotic arterial disease-related mortality in chronic myeloid patients treated with tyrosine kinase inhibitors","volume":"130","author":"Molenaar","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2018.12.013_bib69","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clinthera.2018.12.013_bib70","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929181830612X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929181830612X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:50:02Z","timestamp":1758963002000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014929181830612X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":70,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S014929181830612X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2018.12.013","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Case for Real-world Evidence in the Future of Clinical Research on Chronic Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2018.12.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}